Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose PTCy haploidentical HSCT for poor-prognosis or refractory hematologic malignancies
jRCTs051180144Completed
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 5 more. Primary endpoint: Engrafted survival at day 100. Started Feb 2017; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs051180144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180144.